SCHEMBL1364082

SCHEMBL1364082

COC(=Cc1ccccc1)O[Si](C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
TSHR P16473 1/20 0.38
AKR1C3 P42330 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
RECQL P46063 1/20 0.37
MTNR1A P48039 2/20 0.37
MTNR1B P49286 2/20 0.37
CMA1 P23946 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
FBP1 P09467 1/20 0.35
NR1I2 O75469 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
TRPA1 O75762 1/20 0.34
KDM1A O60341 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9913424 1.00 ALDH1A1 (0.38) ALDH1A1TSHRAKR1C3MEN1KMT2A
SCHEMBL1364080 1.00 ALDH1A1 (0.38) ALDH1A1TSHRAKR1C3MEN1KMT2A
SCHEMBL11419990 0.90 ALDH1A1 (0.42) ALDH1A1TSHRAKR1C3MEN1KMT2A
SCHEMBL57086 0.83 ALDH1A1 (0.46) ALDH1A1TSHRAKR1C3MEN1KMT2A
SCHEMBL11409177 0.80 MEN1 (0.53) ALDH1A1MEN1KMT2ACYP1A2CYP2C19
SCHEMBL11409172 0.80 MEN1 (0.53) ALDH1A1MEN1KMT2ACYP1A2CYP2C19
SCHEMBL8958705 0.80 MEN1 (0.48) ALDH1A1MEN1KMT2ACYP1A2CYP2C19
SCHEMBL8958699 0.80 MEN1 (0.48) ALDH1A1MEN1KMT2ACYP1A2CYP2C19
SCHEMBL10716853 0.75 ALDH1A1 (0.33) ALDH1A1
SCHEMBL28553327 0.74 ALDH1A1 (0.39) ALDH1A1TSHRAKR1C3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2094692-B1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF BRISTOL MYERS SQUIBB CO (US) 2012-11-28 EP disclosed
US-8198311-B2 Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-12 US disclosed
US-8067447-B2 Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2011-11-29 US disclosed
US-20100075961-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2010-03-25 US disclosed
US-20100076014-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2010-03-25 US disclosed
EP-2099767-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF- B ACTIVITY AND USE THEREOF Brystol-Myers Squibb Company (US) 2009-09-16 EP disclosed
EP-2094692-A2 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF Brystol-Myers Squibb Company (US) 2009-09-02 EP disclosed
WO-2008057856-A2 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-15 WO disclosed
WO-2008057857-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-15 WO disclosed
US-5519048-A 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof MERRELL PHARMACEUTICALS INC. (US) 1996-05-21 US disclosed
US-4908451-A Process for preparing α-substituted carbonyl compound AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 1990-03-13 US disclosed
US-4892936-A Process for the preparation or α-azo esters AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 1990-01-09 US disclosed
US-4772714-A Process for the preparation of α-aryl and α-heteroaryl ketones AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) 1988-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075961-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF NFRKB, NR0B1, NFKB2 ALDH1A1 3868/4885TSHR 496/4885AKR1C3 895/4885
US-20100076014-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF NFRKB, NFKBIA, NFKB1 ALDH1A1 3430/4885TSHR 1862/4885AKR1C3 546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.